Olivia Chow vows to bring change to Toronto as she takes office

The ceremony to declare Chow as the 66th Mayor of Toronto offered messages of hope for the city's future but a pledge to get to work with others right away. Mark McAllister reports.

By Jordan Olmstead, The Canadian Press

Olivia Chow encouraged residents to envision a more compassionate and affordable Toronto on Wednesday as she officially took office as mayor in a city facing major housing and financial challenges.

The 66-year-old former NDP MP and past councillor – the first person of colour to lead Canada’s most populous city – drew on themes familiar to her election campaign as she made her first speech as mayor, casting Toronto as a resilient city primed for change.

“Let’s build a Toronto that is more affordable, safe and caring, where everyone belongs,” Chow said to cheers and applause in a packed council chamber.

“Together we can and today, we start.”

Her remarks made overtures to the shortage of affordable housing and a transit system burdened by service cuts, while taking a jab at what she called the city’s “reluctant partners” in the provincial and federal governments for withholding a bailout of Toronto’s pandemic-ravaged finances.

This year’s city budget is short nearly $1 billion, largely driven by increased shelter costs and decreased transit revenues.

“We need a new deal for our city,” Chow said. “Toronto needs strong federal and provincial partners who recognize our city’s crucial role in the economic and social life of our province.”

Chow’s ascension to the city’s top job is a high mark in an enduring political career. She was first elected as a school board trustee in 1985, sat for 13 years on Toronto city council until 2005, and then went to Ottawa as an NDP MP alongside her late husband, former federal New Democrat leader Jack Layton.

She immigrated to Toronto from Hong Kong at 13 years old, settling with her parents in a high-rise apartment in St. James Town, a familiar landing in the downtown core for many working-class newcomers.

“Toronto’s story is also my story,” she said, as she asked those gathered to imagine a young family arriving in the city today with dreams for a better future.

“We all know what they’re up against. So, let’s imagine what could be possible when we meet our challenges with the boundless potential of our ideas and the strength of our collective action.”

Chow defeated 101 other candidates to win last month’s mayoral byelection to replace John Tory, who resigned after admitting to an affair with a staffer. It marked a reversal of her electoral fortunes after finishing third in the 2014 election.

“Toronto’s story has never been about giving up,” she said.

Her declaration of office ceremony, emceed by actor Jean Yoon, featured a reading from the city’s poet laureate and remarks from Indigenous elders. An acapella group led by Lorraine Segato, the frontwoman for Toronto band The Parachute Club, got the chamber to their feet with a rendition of the group’s 1983 hit “Rise Up.”

Chow’s family looked on from the front row as she was introduced with a standing ovation.

“There’s no one I can think of that would do a better job,” said Mike Layton, her stepson and a former city councillor. “To see her back here serving in that capacity, I know it’s something that she feels is great privilege.”

Since the June 26 byelection, Chow has been meeting with city administration, finalizing her team and holding transition engagements with civil service and non-profits on priority issues.

Chow has pledged to get local government back into the business of building social housing and to spend millions to acquire and preserve affordable units.

“We can and must start by tackling the housing crisis,” she said. “The suffering is real.”

Chow’s mayoral term runs until 2026 but will be quickly tested by the city’s turbulent finances.

A city staff report indicates there are enough COVID-19 reserve funds set aside to prop up this year’s budget, but without more money the backstop would be insufficient to cover next year’s projected shortfall of up to $927 million.

Another pressing issue is the city’s housing crisis and the record levels of people experiencing homelessness.

Adding to a sense of urgency, the city has been deadlocked with the federal government over a request to provide more money to help house asylum seekers, with the city recently instituting a policy of turning away those applicants from at-capacity shelters towards federal programs.

Chow would not commit to overturning the controversial policy on Wednesday, even as critics argue it violates the city’s own standards against turning people away based on immigration status. She pressed Ottawa for an additional $160 million to help shelter refugees, calling it a federal responsibility.

A number of issues could test the relationship between Chow and Premier Doug Ford, including the province’s plan to add a privately owned spa to a redesigned Ontario Place. Chow has suggested the city would go to court if the province tried to expropriate city land for the project.

Ford said Wednesday he was “disappointed” by Chow calling the province a reluctant partner.

During the byelection campaign, Ford backed ex-police chief Mark Saunders and said a Chow mayoralty would be an “unmitigated disaster.” He softened his language after her win, highlighting a number of files for potential collaboration, such as transit expansion and housing affordability.

“So that’s what we’re going to be focusing on and hopefully she’ll be open-minded and work collaboratively with us,” he said during a news conference at a meeting of provincial and territorial leaders in Winnipeg.

Keep it Factual
Add CityNews Toronto as a trusted source on Google to see more local stories from us.

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

6h ago

Top Stories

Weight-loss drugs shaping up to be a boon for grocers' pharmacy units

While discount stores have been a bright spot recently for major grocery chains, other units within their empires have been quietly seeing a sales boom: their pharmacies. And it's largely coming from rising sales of weight-loss drugs. The popularity of Ozempic and other GLP-1 drugs, traditionally used to manage Type 2 diabetes, has exploded in recent years thanks to their weight-loss side effects. And as cheaper, generic versions become more widely available, uptake is only expected to rise further. Semaglutides, or GLP-1s as they're sometimes called, are the active ingredient in drugs like Ozempic. For grocers that have pharmacy units, signs of that growth are already noticeable in their financial reports. Loblaw Cos. Ltd., which owns Shoppers Drug Mart and Pharmaprix, reported a roughly 40 per cent surge in GLP-1 sales in each of its last two quarters. "We are beginning to see the impact of GLP-1 drugs going generic. It's still very early, but the initial indications are encouraging," Per Bank, chief executive of Loblaw, told analysts on an earnings call in July. Loblaw executives are projecting double-digit growth for GLP-1 sales in 2027. Metro Inc.'s outgoing chief executive, Eric La Flèche, struck a similar note during its earnings call last month. Metro owns Jean Coutu pharmacies. "Demand fundamentals remain strong with early evidence of increased patient adoption and higher prescription volumes," he said. Loblaw reported its drug retail same-store sales grew 4.6 per cent in its latest quarter, while Metro's pharmacy same-store sales were up 4.8 per cent. Both outpaced same-store sales metrics for food. The gains were driven by the prescriptions category. Even though generic versions of the drug mean lower prices, the growth in volume is still a net positive. "As generic supply continues to build, we expect ongoing expansion of the GLP-1 category to drive low-teens volume and contribution growth," La Flèche told analysts. That's "indicating that higher volumes should more than offset a meaningful portion of the price pressure from generalization," Veritas analyst Kathleen Wong said in a note about Metro's quarterly results in August. "The resulting price deflation is therefore likely to pressure pharmacy same-store sales measured in dollars, but Metro’s early experience suggests that increased accessibility and prescription volumes can offset part of that pressure at the contribution level." Health Canada has so far approved three generic semaglutide products, and is continuing to review more — making the country the first among G7 nations to do so. These used to be called the drug of the rich, said Amar Singh, senior director and head of Canadian retail insights at Kantar. "This drug was expensive, and now, with the generics coming out, this is increasing penetration as the cost has come down and more people can afford it," he said in an interview. Half of the respondents in a Leger poll from March said insurance coverage or a lower-cost generic would increase their likelihood of using a GLP-1. More than half cited weight loss as their primary reason for taking the drug. At that time, eight per cent — or three million Canadians — were on prescription GLP-1s, the survey suggested. With generics increasingly available in the market, Singh said he expects uptake to rise to about 20 per cent over the next year or two. That surge comes as Loblaw and Metro are expanding their pharmacy networks. Loblaw expects to have opened about 200 stores over the last three years, and roughly half are pharmacies, Wong said. Meanwhile, Empire acquired nine Morelli’s pharmacies in Ontario last month that are already situated within some Longo’s grocery stores. Jo-Ann McArthur, president of Nourish Food Marketing, said the increasing popularity of weight-loss drugs could be an opportunity for grocers to tailor customer experiences, especially as attitudes toward food change among weight-loss drug users. For instance, she said grocers could suggest GLP-1-friendly foods and offer meal planning through their loyalty apps, offer health-care insights for those on and off drugs, streamline store shelf labelling and market items that are weight-loss drug friendly. Late last year, Loblaw launched an online weight-management program for people to connect with health care practitioners and see if they qualify for the drugs. "Where they make more money (is) by providing more services and more advice and just making it easier for the consumer to just stay loyal," she said. And it's not just about keeping GLP-1 users within the same ecosystem. "People who are on these drugs often are controlling the whole family's shopping and meal prep," she said. "If one person in a family is on a diet, the whole family is on a diet." This report by The Canadian Press was first published Sept. 13, 2026.

6h ago

Most Watched Today